Flamel Technologies (Nasdaq:FLML) announced today that the Board
of Directors has elected Dr. Frank J. Fildes, PhD to serve as a member
of the Company’s Board of Directors. Dr. Fildes was elected to replace
Cor Boonstra, who is retiring from his position with Flamel. Dr.
Fildes will also assume Mr. Boonstra’s pos…
March 7, 2000 (Lake Worth, Fla.) — A new study shows that a blood-pressure
medication that physicians have traditionally been reluctant to use in people
with heart failure can significantly improve their chances of survival and
their quality of life.
The drug, Toprol XL (me…
CHICAGO & LONDON — This is a repeat of the version issued yesterday.
The Fitch Ratings global pharmaceutical team today published its ‘Quarterly Global Pharmaceutical R&D Pipeline’ report for the second quarter. The overview details the mos…
Branded drugs” domination of a market slips away with each generic launch. “Global sales of generic drugs will grow more than 20 percent annually to reach $80 billion by 2008, as healthcare providers turn increasingly to less-expensive, unpatented medicines,” said Graham Lewis, IMS vice president for pharma s…
Decision Resources (Waltham, MA), one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of key therapies, most notably GlaxoSmithKline’s Coreg and Roche’s Dilatrend/Kredex, will cause the chronic heart failure…
Flamel Technologies (Nasdaq: FLML) announced today that a payment
of $500,000 has been triggered in connection with the license
agreement it signed in 2007 with Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE). The agreement is for the development of a marketed
protein to be delivered using Flamel’s Medusa technology. …
